Combination therapies for inner ear sensory hair cell regeneration/replacement

A composition and biodegradation technology, applied in sensory diseases, animal cells, nervous system cells, etc., can solve problems such as unclear effects

Active Publication Date: 2019-04-02
HOUGH EAR INST
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, the safety and efficacy of GSK-3 inhibitors (GSK3I) have been tested in animal models; ho

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapies for inner ear sensory hair cell regeneration/replacement
  • Combination therapies for inner ear sensory hair cell regeneration/replacement
  • Combination therapies for inner ear sensory hair cell regeneration/replacement

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0140] Example 1 - Generation of siHes1 nanoparticles and their evaluation

[0141] generate loaded nanoparticles

[0142] siRNA-loaded PLGA nanoparticles prepared for this study were previously reported (Cun et al. (2010) Intl.J.Pharmaceutics 390:70-75; Du et al. (2013) Hear.Res.304C:91-110 ) of water-in-oil-in-water (wl / o / w2) double emulsion solvent evaporation method to prepare. Briefly, siRNA was dissolved in 50 μL of TE buffer (10 mM Tris-HCl and 1 mM EDTA in MilliQ water, pH 7.5) and mixed with 100 mL of dichloromethane (DCM) containing 100 mg PLGA, and the mixture was sonicated Emulsifies into a primary wl / o emulsion. 4 mL of 5% (w / v) polyvinyl alcohol (PVA) in MilliQ aqueous solution was directly poured into the primary emulsion, which was then further emulsified by sonication for 30 s × 3 to form a wl / o / w2 double emulsion. The resulting emulsion was diluted with 50 mL of 0.3% (w / v) PVA in MilliQ in water and stirred magnetically at room temperature for 2 hours ...

Embodiment 2

[0173] Example 2 - BIO and Hes1 siRNA

[0174] Undamaged PC

[0175] Organotypic cultures from murine cochleae were grown and then harvested from CD1 mice at postnatal day 3 (P3). These explants were then cultured in appropriate medium for 24 hours. At the equivalent of P4 (i.e., 24 h ex vivo), cultured Organs of Corti (OC, i.e. cochlear sensory epithelial cells) were immersed in DMSO (vehicle) or the GSK3 inhibitor 6-bromoindirubin-3 '-oxime (BIO) in fresh medium, and correspondingly cultured OC for 72 hours. A subset of cultures from both treatment groups (jetSI 10 mM, PolyPlusTransfection, Illkirch, France) were transfected with 20 nM Hes1 siRNA for 24 hours corresponding to P7 (ie 96 hours ex vivo). To examine the effect of sequential administration, siHes1 was transfected in medium without BIO. To examine the effect of simultaneous administration, siHes1 was transfected in BIO-containing medium. Following the 24 hour transfection culture period, sequentially trea...

Embodiment 3

[0179] Example 3 - TIDE and Hes1 siRNA

[0180] Analysis of Tideglusib

[0181] Tideglusib was purchased from Cayman Chemical Company and was subjected to dose curve analysis under serum starvation conditions in which dog kidney passage (Madin-Darby Canine Kidney, MDCK) cells were paralleled with a series of commercially available GSK3 inhibitors to determine its efficacy under mitotic arrest conditions. Relative proliferative potential in a mature mammalian epithelial cell line. In these experiments, MDCK cells were cultured for 24 hours under serum starvation conditions and then treated with a GSK3 inhibitor and 10 μM EdU (5-ethynyl-2'-deoxyuridine), a permanent marker of cells undergoing DNA replication. The cells were cultured for 48 hours in the presence of nucleoside analogs).

[0182] Figure 19 An example of this type of analysis is depicted in . Each of the GSK3 inhibitors tested exhibited a clear positive effect on cell proliferation at the lowest doses teste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to compositions and methods for the regeneration and/or restoration of hair cells utilizing a composition or an agent that decreases expression of a gene in a tissue ofthe inner ear and a second agent.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. 119(e) to U.S. Serial No. 62 / 345,740, filed June 3, 2016, the entire contents of which are incorporated herein by reference. Background technique [0003] Deafness and balance impairment are common human disabilities. In most cases, these disabilities are caused by (1) the organ of Corti (OC) in the cochlea, (2) the vestibular epithelium in the cristae, or (3) the sacculus or utricle of the vestibular organ. Caused by loss of sensory hair cells. Currently, there are no FDA-approved treatments that can cure these diseases by restoring sensory hair cells in these tissues. [0004] Current approaches to this problem involve vestibular rehabilitation to accommodate damage to the vestibular organs. Rehabilitation is time consuming and does not restore lost function. For sensorineural hearing loss, rehabilitation can be done with hearing aids or cochlear implants. However, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00A61K38/17C07H21/04C12N15/87C12N5/0793
CPCA61K9/5153C12N2310/3517C12N2320/32A61K45/06A61K31/713A61K9/0009A61K9/0046A61K9/1647A61K31/404A61K31/433A61K38/1825A61K41/00C12N15/113C12N2310/14C12N2320/31A61P27/16A61P43/00A61K2300/00A61K31/7105
Inventor 马修·B·韦斯特理查德·D·科普克
Owner HOUGH EAR INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap